139 related articles for article (PubMed ID: 35904914)
1. [An "a la carte" treatment for patients with pancreatic adenocarcinoma].
Iovanna J; Dusetti N
Medicina (B Aires); 2022; 82(4):571-573. PubMed ID: 35904914
[TBL] [Abstract][Full Text] [Related]
2. Speeding towards individualized treatment for pancreatic cancer by taking an alternative road.
Iovanna J; Dusetti N
Cancer Lett; 2017 Dec; 410():63-67. PubMed ID: 28947138
[TBL] [Abstract][Full Text] [Related]
3. [Personalized cancer medicine : Biomarkers for molecular therapy stratification in pancreatic carcinoma].
Ormanns S
Pathologe; 2018 Dec; 39(Suppl 2):221-224. PubMed ID: 30361776
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
Zemanek T; Melichar B; Lovecek M; Soucek P; Mohelnikova-Duchonova B
Pharmacogenomics; 2019 Jan; 20(2):113-127. PubMed ID: 30539680
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
Pishvaian MJ; Brody JR
Oncology (Williston Park); 2017 Mar; 31(3):159-66, 168. PubMed ID: 28299752
[TBL] [Abstract][Full Text] [Related]
6. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.
Birnbaum DJ; Bertucci F; Finetti P; Birnbaum D; Mamessier E
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):248-255. PubMed ID: 29499330
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier.
Bhasin MK; Ndebele K; Bucur O; Yee EU; Otu HH; Plati J; Bullock A; Gu X; Castan E; Zhang P; Najarian R; Muraru MS; Miksad R; Khosravi-Far R; Libermann TA
Oncotarget; 2016 Apr; 7(17):23263-81. PubMed ID: 26993610
[TBL] [Abstract][Full Text] [Related]
8. Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer.
Liu B; Fu T; He P; Du C; Xu K
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34143198
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
10. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
Sahin IH; Lowery MA; Stadler ZK; Salo-Mullen E; Iacobuzio-Donahue CA; Kelsen DP; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):893-905. PubMed ID: 26881472
[TBL] [Abstract][Full Text] [Related]
11. Genomics of pancreatic ductal adenocarcinoma.
Pilarsky C; Grutzmann R
Hepatobiliary Pancreat Dis Int; 2014 Aug; 13(4):381-5. PubMed ID: 25100122
[TBL] [Abstract][Full Text] [Related]
12. Current and future biomarkers for pancreatic adenocarcinoma.
Loosen SH; Neumann UP; Trautwein C; Roderburg C; Luedde T
Tumour Biol; 2017 Jun; 39(6):1010428317692231. PubMed ID: 28618958
[TBL] [Abstract][Full Text] [Related]
13. Translational genomics in pancreatic ductal adenocarcinoma: A review with re-analysis of TCGA dataset.
Ho J; Li X; Zhang L; Liang Y; Hu W; Yau JCW; Chan H; Gin T; Chan MTV; Tse G; Wu WKK
Semin Cancer Biol; 2019 Apr; 55():70-77. PubMed ID: 29705685
[TBL] [Abstract][Full Text] [Related]
14. Integrated bioinformatics analysis identified COL11A1 as an immune infiltrates correlated prognosticator in pancreatic adenocarcinoma.
Zheng X; Liu X; Zheng H; Wang H; Hong D
Int Immunopharmacol; 2021 Jan; 90():106982. PubMed ID: 33129696
[TBL] [Abstract][Full Text] [Related]
15. Identification of an extracellular vesicle-related gene signature in the prediction of pancreatic cancer clinical prognosis.
Xu D; Wang Y; Zhou K; Wu J; Zhang Z; Zhang J; Yu Z; Liu L; Liu X; Li B; Zheng J
Biosci Rep; 2020 Dec; 40(12):. PubMed ID: 33169793
[TBL] [Abstract][Full Text] [Related]
16. Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment.
Le Large TY; Mato Prado M; Krell J; Bijlsma MF; Meijer LL; Kazemier G; Frampton AE; Giovannetti E
Expert Rev Mol Diagn; 2016 Jul; 16(7):733-6. PubMed ID: 27118062
[TBL] [Abstract][Full Text] [Related]
17. Screening and validating the core biomarkers in patients with pancreatic ductal adenocarcinoma.
Li Y; Zhu YY; Dai GP; Wu DJ; Gao ZZ; Zhang L; Fan YH
Math Biosci Eng; 2019 Nov; 17(1):910-927. PubMed ID: 31731384
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma.
Chen DT; Davis-Yadley AH; Huang PY; Husain K; Centeno BA; Permuth-Wey J; Pimiento JM; Malafa M
PLoS One; 2015; 10(8):e0133562. PubMed ID: 26247463
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-132 Plays an Independent Prognostic Role in Pancreatic Ductal Adenocarcinoma and Acts as a Tumor Suppressor.
Chen Y; Zhu H; Wang Y; Song Y; Zhang P; Wang Z; Gao J; Li Z; Du Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033818824314. PubMed ID: 30803373
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic cancer: the role of molecular markers in diagnosis and management.
Lowery MA; O'Reilly EM
Clin Adv Hematol Oncol; 2011 Dec; 9(12):900-8. PubMed ID: 22252658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
